CVRx

CVRx, Inc. is a pioneering commercial-stage public company based in Minneapolis, Minnesota, dedicated to the advancement of healthcare through innovative medical devices. Established in 2001, CVRx has emerged as a leader in the field of cardiovascular disease management, focusing on the development, manufacturing, and commercialization of neuromodulation solutions aimed specifically at treating heart failure. Their flagship product, Barostim, represents the world's first neuromodulation device designed to address heart failure by leveraging the body's natural baroreflex. This implantable device works by stimulating the carotid baroreceptors, essential sensors that help regulate blood flow and cardiovascular function.

At the core of CVRx's mission is the commitment to improving patient outcomes and quality of life for individuals suffering from heart failure. The company prides itself on its robust scientific research and development, aiming to create therapies that not only alleviate symptoms but also enhance the overall health and well-being of patients. With a talented leadership team and a rich history of innovation, CVRx is positioned to continue making significant strides in the medical devices industry, contributing to advancements in the treatment of cardiovascular diseases as well as the betterment of healthcare systems worldwide.